文献速递肿瘤 PET/CT核素与放射性配体治疗

消融后即刻注射18F-FDG及其对应SUV可作为结直肠癌肝转移热消融后局部肿瘤进展的替代生物标志物

Immediate Postablation 18F-FDG Injection and Corresponding SUV Are Surrogate Biomarkers of Local Tumor Progression After Thermal Ablation of Colorectal Carcinoma Liver Metastases.
PubMed 文献 · J Nucl Med · 2018-02-09

这项前瞻性研究纳入39例患者共62次消融,评估术中18F-FDG PET/CT预测结直肠癌肝转移消融后局部肿瘤进展的价值。活检阳性组SUV比值显著高于阴性组,且活检阳性与最小消融边缘<5 mm者局部进展率更高;在活检阴性消融中,最小边缘距离和SUV比值可独立预测局部肿瘤进展。

要点

  • 消融后即刻活检阳性者SUV比值显著高于阴性者(85.8±92.2 vs 42.3±45.5,P=0.03)。
  • 活检阳性者局部进展率80%(8/10)显著高于阴性者29%(15/52)(P=0.001)。
  • 活检阴性消融中,最小边缘距离和SUV比值可独立预测局部肿瘤进展。

核心结论

  • 当消融后即刻活检未见存活肿瘤细胞时,SUV比值和最小消融边缘距离可独立预测结直肠癌肝转移消融后的局部肿瘤进展。

研究设计与样本

  • 经机构审查委员会批准的前瞻性研究,39例患者(19男20女,中位年龄56岁)接受分次剂量18F-FDG PET/CT引导消融,随后即刻活检及增强CT成像。
  • 共评估62次连续消融;活检组织按仅见非存活凝固性坏死或存活肿瘤细胞进行二分类。
  • 增强CT的最小消融边缘分为0 mm、1-4 mm、5-9 mm或≥10 mm;SUV比值由消融区和周围正常肝的三维感兴趣区计算。
  • 采用竞争风险回归模型(单因素和多因素分析)评估活检、最小边缘距离和SUV比值对影像学识别的局部肿瘤进展时间的预测价值。

主要发现

  • 消融后即刻活检存活肿瘤阳性者(n=10)平均SUV比值显著高于阴性者(n=52)(85.8±92.2 vs 42.3±45.5,P=0.03)。
  • 最小边缘<5 mm者(n=15)平均SUV比值显著高于最小边缘≥5 mm者(n=47)(78.5±99.1 vs 38.3±78.5,P=0.01)。
  • 中位随访22.5个月(范围7-52个月)后,62个消融肿瘤中23个出现局部肿瘤进展(37.1%)。
  • 活检存活肿瘤阳性者局部进展率显著高于阴性者(80%[8/10] vs 29%[15/52],P=0.001)。
  • 最小边缘<5 mm者局部进展率显著高于最小边缘≥10 mm者(60%[9/15] vs 13%[2/15],P=0.02),但与5-9 mm者(37.5%[12/32])无显著差异(P=0.5)。

关键数值与推荐

  • 活检组织二分类标准:仅见非存活凝固性坏死或可见存活肿瘤细胞。
  • 最小消融边缘分类:0 mm、1-4 mm、5-9 mm或≥10 mm。
  • SUV比值由消融区和周围正常肝的三维感兴趣区计算。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The aim of this study was to determine whether intraprocedural 18F-FDG PET/CT can be used as a predictor of local tumor progression after percutaneous ablation of colorectal liver metastases. Methods: In this institutional review board-approved prospective study, 39 patients (19 men and 20 women; median age, 56 y) underwent split-dose 18F-FDG PET/CT-guided ablation followed by immediate biopsy and contrast-enhanced CT imaging of the ablation zone. Binary categorization of biopsy tissues was performed on the basis of the presence of only nonviable coagulation necrosis or viable tumor cells. Minimum ablation margin measurements from contrast-enhanced CT imaging were categorized as 0 mm, 1-4 mm, 5-9 mm, or greater than or equal to 10 mm. SUVs were obtained from PET/CT imaging, and SUV ratios were calculated from 3-dimensional regions of interest located in the ablation zone and surrounding normal liver. All predictive variables (biopsy, minimum margin distance, and SUV ratio) were evaluated as predictors of time to local tumor progression identified on imaging using competing-risks regression models (uni- and multivariate analyses). Results: A total of 62 consecutive ablations were evaluated. The mean SUV ratio was significantly higher for viable tumor-positive immediate postablation biopsies (n = 10) than for tumor-negative biopsies (n = 52) (85.8 ± 92.2 vs. 42.3 ± 45.5) (P = 0.03) and for a minimum margin size of less than 5 mm (n = 15) than for a minimum margin size of greater than or equal to 5 mm (n = 47) (78.5 ± 99.1 vs. 38.3 ± 78.5) (P = 0.01). After a median follow-up period of 22.5 (range, 7-52) months, 23 of 62 ablated tumors showed local tumor progression (37.1%). The local tumor progression rate was significantly higher for viable tumor-positive biopsies (8/10) than for negative biopsies (15/52) (80% vs. 29%) (P = 0.001) and for a minimum margin size of less than 5 mm (9/15) than for a minimum margin size of greater than or equal to 10 mm (2/15) (60% vs. 13%) (P = 0.02) but not 5-9 mm (37.5%; 12/32) (P = 0.5). In a competing-risks analysis, biopsy results (P = 0.07) and the minimum margin size (P = 0.08) were borderline significant, but the SUV ratio was not (P = 0.22). However, for negative biopsy ablations, the minimum margin size and SUV ratio were predictive imaging factors for local tumor progression; subdistribution hazard ratios were 0.564 (0.325-0.978) (P = 0.04) and 1.005 (1.001-1.009) (P = 0.005), respectively. Conclusion: The SUV ratio and minimum margin size can independently predict colorectal metastasis local tumor progression after liver ablation when there are no viable tumor cells on immediate postablation biopsies.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Cornelis FH, Petre EN, Vakiani E, et al. Immediate Postablation 18F-FDG Injection and Corresponding SUV Are Surrogate Biomarkers of Local Tumor Progression After Thermal Ablation of Colorectal Carcinoma Liver Metastases. J Nucl Med. 2018. PMID: 29439012. doi:10.2967/jnumed.117.194506

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。